Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Semnur Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2023
FY2024
FY2025
Research and development
1.71
2.55
General and administrative
2.98
158
Operating expenses
4.69
160
Operating income
-3.17
-4.69
-160
Interest expense
0.04
0.1
Interest income
1.22
3.84
1.58
Pre-tax income
0
0
Income tax
0
0
Net income
-0.42
0.63
-4.69
-160
EBITDA
-4.69
-160
EPS, basic
-0.02
-0.78
EPS, diluted
-0.02
-0.78
Shares, basic (weighted)
200
205
Shares, diluted (weighted)
200
205
Balance sheet
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.82
0.2
0.01
0.02
Other current assets
0.09
0
5.98
0
Total current assets
0.91
0.21
6
0.6
Property, plant and equipment
0.69
0.75
Total assets
86.3
50.7
6.68
1.35
Accounts payable
1.29
0
5.91
Accrued liabilities
0.04
0.74
Total current liabilities
1.29
5.6
0.04
10.2
Total liabilities
4.18
8.49
49.5
22.1
Paid-in capital
0
72.6
255
Retained earnings
-3.27
-8.28
-115
-276
Shareholders' equity
-3.27
-38.1
-42.8
-20.8
Total equity
-3.27
-38.1
-42.8
-20.8
Total liabilities and equity
86.3
50.7
6.68
1.35
Shares outstanding
200
230
Cash flow statement
FY2022
FY2023
FY2024
FY2025
Net income
-0.42
0.63
-4.69
-160
Depreciation and amortization
0
0
Stock-based compensation
0.66
142
Change in payables
1.29
2.46
0
2.15
Cash from operations
-0.43
-0.63
-4.89
-5.87
Purchases of investments
-84.2
-0.83
Cash from investing
-84.2
39.7
43.4
Share buybacks
-40.5
-43.4
Cash from financing
85.4
-39.7
4.89
5.88
Net change in cash
0.82
-0.62
0
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.31 on November 9, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-8,630.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
-79.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-75.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
2.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.11x
Current assets / current liabilities.
Quick ratio
0.00x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.05
Cash from operations / diluted weighted shares.
Book value per share
-$0.13
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-235.0%
Net income / market cap (the inverse of P/E).
Was Semnur Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $160.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.